Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) is now available.
Zylox-Tonbridge Medical Technology Co., Ltd. has called its 2025 annual general meeting for May 13, 2026, in Hangzhou, where shareholders will review the 2025 board, supervisory committee, financial and independent director reports, decide on the profit distribution plan, and reappoint the external auditor. Investors will also vote on amendments to the H Share Award and Trust Scheme, grant general mandates for share issuance and H-share repurchases, and consider major governance changes including altering the company’s operating term and cancelling the supervisory committee through amendments to the articles of association, potentially reshaping its capital management flexibility and corporate oversight framework.
The most recent analyst rating on (HK:2190) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a PRC-incorporated medical technology company listed in Hong Kong, focusing on developing and commercializing medical devices. Its operations are centered on products and technologies for healthcare markets, with oversight from a board of directors and, currently, a supervisory committee as part of its governance structure.
Average Trading Volume: 770,015
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$8.33B
For detailed information about 2190 stock, go to TipRanks’ Stock Analysis page.